Theravance Biopharma Inc. (TBPH)
| Bid | 8.51 |
| Market Cap | 433.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.15 |
| PE Ratio (ttm) | -7.62 |
| Forward PE | 10.05 |
| Analyst | Hold |
| Ask | 9.75 |
| Volume | 174,093 |
| Avg. Volume (20D) | 233,366 |
| Open | 8.82 |
| Previous Close | 9.01 |
| Day's Range | 8.73 - 8.99 |
| 52-Week Range | 7.44 - 10.90 |
| Beta | 0.14 |
About TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical tr...
Analyst Forecast
According to 4 analyst ratings, the average rating for TBPH stock is "Hold." The 12-month stock price forecast is $12.5, which is an increase of 42.61% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call TranscriptTheravance Biopharma, Inc. (NASDAQ:TBPH ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Business Of...
